Johnson & Johnson (NYSE:JNJ) announced that Memorial Hermann-Texas Medical Center in Houston, Texas, will become the first hospital to install its Ottava robotic surgical system, marking the beginning of the company’s early access commercial programme for the technology.
The installation represents an important step in Johnson & Johnson’s expansion into robotic-assisted surgery following the US Food and Drug Administration’s De Novo authorisation of the Ottava platform in July 2026.
The company describes Ottava as the first FDA-authorised table-integrated robotic surgical system designed for soft-tissue procedures.
The platform is authorised for ten general surgery procedures and incorporates four robotic arms into a standard-sized operating table, alongside software-controlled automation, specialised surgical instruments and digital connectivity.
Johnson & Johnson plans to expand the commercial rollout to selected US hospitals while continuing to evaluate the system for additional surgical applications.
Johnson & Johnson secured FDA De Novo authorisation for the Ottava robotic surgical system in July 2026, establishing a regulatory pathway for its initial commercial introduction in the United States.
The authorisation covers ten general surgery procedures, providing the company with an initial range of clinical applications for the technology.
These procedures include Roux-en-Y gastric bypass, gastrectomy, cholecystectomy, splenectomy and sleeve gastrectomy.
The system is also authorised for small bowel resection, appendectomy, lysis of adhesions, fundoplication and hiatal hernia repair.
The range of authorised procedures allows the platform to be used across several areas of abdominal and gastrointestinal surgery.
The FDA authorisation represents a significant regulatory milestone for Johnson & Johnson’s surgical robotics programme, enabling the company to begin introducing Ottava to selected healthcare providers.
The Ottava system differs from conventional robotic surgical platforms through its integration of four robotic arms directly into a standard-sized surgical table.
The design combines robotic instrumentation with the operating table rather than relying on a separate robotic structure positioned alongside the patient.
Johnson & Johnson has incorporated software-controlled automation into the system, alongside robotic instruments designed to support the authorised surgical procedures.
The platform is also compatible with the company’s Polyphonic digital ecosystem, providing connectivity with its broader surgical technology infrastructure.
These features form part of Johnson & Johnson’s strategy to develop an integrated robotic surgery platform combining hardware, software and digital capabilities.
The table-integrated design is a central element of the system’s architecture and distinguishes Ottava from other approaches to robotic-assisted surgery.
Memorial Hermann-Texas Medical Center in Houston will be the first hospital to install Ottava as Johnson & Johnson begins its early access commercial programme.
The hospital previously participated in the clinical evaluation of the system, serving as a trial site under an Investigational Device Exemption programme.
The clinical programme supported the regulatory submission that led to the FDA’s authorisation of Ottava in July 2026.
Its involvement in the earlier clinical studies provides continuity between the platform’s development and its initial commercial deployment.
The selection of Memorial Hermann-Texas Medical Center marks the transition from clinical investigation to early commercial availability at selected US healthcare institutions.
Johnson & Johnson has not disclosed the financial terms associated with the installation or provided a detailed timetable for subsequent hospital deployments.
Tim Schmid, Executive Vice President and Worldwide Chairman of MedTech at Johnson & Johnson, described the first installation as an important development in the company’s surgical robotics strategy.
“Today’s milestone is a significant step for Johnson & Johnson as we commercialize Ottava and continue building on our ambition to lead in surgical robotics,” Schmid said.
The announcement reflects the company’s efforts to establish a commercial presence in robotic-assisted soft-tissue surgery.
The Ottava platform forms part of Johnson & Johnson’s broader medical technology portfolio, with the company seeking to combine robotic systems, surgical instruments and digital capabilities.
The initial deployment will provide an opportunity to introduce the technology into a commercial hospital environment following its clinical evaluation and regulatory authorisation.
Memorial Hermann-Texas Medical Center previously participated in the clinical investigation of Ottava under the FDA’s Investigational Device Exemption framework.
Erik Wilson, M.D., chief of minimally invasive and elective general surgery at UTHealth Houston, served as lead investigator for the FORTE clinical study.
Wilson also commented on the installation announcement, although the supplied company update did not include the text of his remarks.
Johnson & Johnson disclosed that Wilson is a paid consultant to the company.
The FORTE study formed part of the clinical development programme supporting Ottava’s regulatory evaluation.
The hospital’s participation in the programme established an existing relationship with the technology before its selection as the first installation site.
Following the initial installation in Houston, Johnson & Johnson intends to continue introducing Ottava to selected customers across the United States.
The company is pursuing an early access commercial strategy rather than announcing an immediate broad-scale rollout.
This approach will allow the company to expand the system’s availability while supporting its introduction into participating healthcare facilities.
Johnson & Johnson also plans to evaluate Ottava for additional surgical indications beyond the ten general surgery procedures covered by its existing FDA authorisation.
Any expansion into new indications would depend on the relevant clinical evaluation and regulatory requirements.
The company has not announced a specific number of planned installations, a wider commercial launch date or financial targets associated with the platform.
The first planned installation of Ottava at Memorial Hermann-Texas Medical Center represents a significant step in Johnson & Johnson’s efforts to commercialise its robotic-assisted surgery technology.
Following FDA De Novo authorisation in July 2026, the company is moving into an early commercial phase with a platform designed for ten general surgery procedures.
Ottava’s four table-integrated robotic arms, software-controlled automation and compatibility with the Polyphonic digital ecosystem are central features of the technology.
The selection of a hospital previously involved in the system’s clinical investigation also connects the initial commercial deployment with Johnson & Johnson’s earlier development programme.
Looking ahead, the company’s progress will depend on the pace of installations at selected US hospitals, adoption of the technology by surgical teams and the outcome of further evaluations for additional procedures.
The announcement establishes an initial commercial milestone for Ottava, although the broader financial contribution of the robotic surgery platform remains to be determined.
Johnson & Johnson stock price
| 40 min | |
| 2 hours | |
| Nov-18 | |
| Nov-17 | |
| Nov-17 | |
| Nov-17 | |
| Nov-16 | |
| Nov-16 |
J&J outlays up to $3.3bn to buy ophthalmology specialist Ollin Biosciences
JNJ
Pharmaceutical Technology
|
| Nov-16 | |
| Nov-16 | |
| Nov-16 | |
| Nov-16 | |
| Nov-16 | |
| Nov-16 | |
| Nov-16 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, alerts, and much more.
Learn more about Finviz Elite